Inhibrx Stock
INBX Stock ,The shares of Inhibrx (INBX -1.47 percent) A biotechnology company that is in the process of establishing a clinical phase company, rose as the market opened on Tuesday. Investors ecstatic about the company’s most recent clinical trial report increased the price 26.8 percent higher at 11.29 a.m. today.
What’s the question?
This morning, Inhibrx released top-line results of a first-ever trial using INBRX 101. This is the company’s customized form of antitrypsin alpha-1 (AAT) which is which is a protein that helps protect lung tissue.
A deficiency of AAT is treatable by weekly infusions of a chemical extracted from plasma of humans. Inhibrx created INBRX-101 to stay in therapeutic levels for at most several weeks following every infusion.
The news today is that Inhibrx has announced encouraging findings from the first phase of a dose determination study which suggests that the biotech is on the right path. Patients receiving multiple doses INBRX-101 each week for three weeks had AAT levels that were functional at doses that were above levels of the target for conventional replacement therapy.
What do we do now?
A total of 100,000 Americans are suffering from AAT deficiency. A new treatment that significantly reduces the frequency of infusions could bring over $1 billion annually in sales. In the past season, markets crashed the shares Vertex Pharmaceuticals (VRTX 1.20%) following the announcement that an oral treatment for AAT deficiency did not reach the high standards of the course of a clinical trial.
The gains that Inhibrx is making today could be even greater were it not for two drug candidates for RNA interference currently in mid-stage clinical trials. In the coming this year Arrowhead Pharmaceuticals will wrap its phase 2 trial that includes ARO-AAT. Belcesiran from the partners Dicerna as well as Alnylam is also being studied in an ongoing phase 2 study with top-line results expected to be announced next year.
Inhibrx Returns in comparison to. S&P
| 1 YEAR | 5 YEAR | 5 YEAR ANNUALIZED | SINCE IPO | |
|---|---|---|---|---|
| INBX | -6.39% | +21% | ||
| S&P | -8.65% | +53.30% | +8.92% | +22% |
Assets
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Net Cash | $146.07M | +29.6% |
| Accounts Receivable | $0.32M | -37.4% |
| Inventory | 0 | – |
Liabilities
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Long Term Debt | $174.48M | +131.0% |
| Short Term Debt | $1.81M | +11.2% |
Ratios
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Return On Assets | -85.4% | +48.8% |
| Return On Invested Capital | -253.6% | -6.5% |
Cash Flow
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Free Cash Flow | -$30.39M | +125.8% |
| Operating Free Cash Flow | -$30.41M | +128.8% |
Valuation
QUARTERLYANNUAL
| Q4 2021 | Q1 2022 | Q2 2022 | Q3 2022 | YOY CHANGE | |
|---|---|---|---|---|---|
| Price to Earnings | – | – | – | – | – |
| Price to Book | 58.74 | 16.58 | 16.20 | -142.38 | – |
| Price to Sales | 233.65 | 120.12 | 63.35 | 147.96 | -16.2% |
| Price to Tangible Book Value | 58.74 | 16.58 | 16.20 | -142.38 | – |
| Price to Free Cash Flow TTM | – | – | – | – | – |
| Enterprise Value to EBITDA | -87.05 | -29.69 | -13.05 | -24.98 | -63.1% |
| Free Cash Flow Yield | – | – | – | – | – |
| Return on Equity | -130.5% | -127.9% | -213.2% | -562.3% | – |
| Total Debt | $77.18M | $115.45M | $175.70M | $176.29M | +128.4% |
